当前位置: 首页 >> 检索结果
81. PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.
作者: Michael Trauner.;Chuhan Chung.;Kate Sterling.;Xiangyu Liu.;Xiaomin Lu.;Jun Xu.;Clare Tempany-Afdhal.;Zachary D Goodman.;Martti Färkkilä.;Atsushi Tanaka.;Palak Trivedi.;Kris V Kowdley.;Christopher L Bowlus.;Cynthia Levy.;Robert P Myers.
来源: BMC Gastroenterol. 2023年23卷1期75页
Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease leading to biliary fibrosis and cirrhosis. Cilofexor is a nonsteroidal farnesoid X receptor agonist that demonstrated significant improvements in liver biochemistry and markers of cholestasis in patients with PSC in a phase 2 study. We describe here the rationale, design, and implementation of the phase 3 PRIMIS trial, the largest placebo-controlled trial in PSC.
82. The Efficacy of Peroral Endoscopic Myotomy vs Pneumatic Dilation as Treatment for Patients With Achalasia Suffering From Persistent or Recurrent Symptoms After Laparoscopic Heller Myotomy: A Randomized Clinical Trial.
作者: Caroline M G Saleh.;Pietro Familiari.;Barbara A J Bastiaansen.;Paul Fockens.;Jan Tack.;Guy Boeckxstaens.;Raf Bisschops.;Aaltje Lei.;Marlies P Schijven.;Jan Guido Costamagna.;Albert J Bredenoord.
来源: Gastroenterology. 2023年164卷7期1108-1118.e3页
For patients with achalasia experiencing persistent or recurrent symptoms after laparoscopic Heller myotomy (LHM), pneumatic dilation (PD) is the most frequently used treatment. Per-oral endoscopic myotomy (POEM) is increasingly being investigated as rescue therapy. This study aimed to determine the efficacy of POEM vs PD for patients with persistent or recurrent symptoms after LHM.
83. Interactive training versus self-driven training in the prediction of colorectal polyp histology by trainees using the NICE classification.
The COVID-19 pandemic has impacted endoscopic training of the Narrow Band Imaging International Colorectal Endoscopic (NICE) classification, which could accurately predict pathology of colorectal polyps. This study aimed to evaluate the diagnostic performance by trainees of self-driven training vs. interactive training in the prediction of colorectal polyp histology.
84. Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation.
作者: Satish S C Rao.;Eamonn M M Quigley.;William D Chey.;Amol Sharma.;Anthony J Lembo.
来源: Gastroenterology. 2023年164卷7期1202-1210.e6页
Despite therapeutic advances, effective treatments for chronic constipation remain an unmet need. The vibrating capsule is a nonpharmacologic, orally ingested, programmable capsule that vibrates intraluminally to induce bowel movements. We aimed to determine the efficacy and safety of the vibrating capsule in patients with chronic constipation.
85. Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial.
作者: Bhagabati Ghimire.;Rebecca Landy.;Roberta Maroni.;Samuel G Smith.;Irene Debiram-Beecham.;Peter D Sasieni.;Rebecca C Fitzgerald.;Greg Rubin.;Fiona M Walter.;Jo Waller.; .;Judith Offman.
来源: BMC Gastroenterol. 2023年23卷1期7页
The Cytosponge is a cell-collection device, which, coupled with a test for trefoil factor 3 (TFF3), can be used to diagnose Barrett's oesophagus, a precursor condition to oesophageal adenocarcinoma. BEST3, a large pragmatic, randomised, controlled trial, investigated whether offering the Cytosponge-TFF3 test would increase detection of Barrett's. Overall, participants reported mostly positive experiences. This study reports the factors associated with the least positive experience.
86. Establishment and evaluation of an early prediction model of hepatorenal syndrome in patients with decompensated hepatitis B cirrhosis.
作者: Shouhao Wang.;Zhewen Zhou.;Chengan Xu.;Hanzhu Chen.;Wenya Ren.;Xingdi Yang.;Qiaoqiao Yin.;Wei Zheng.;Hongying Pan.
来源: BMC Gastroenterol. 2023年23卷1期1页
In China, hepatorenal syndrome is a serious complication in the decompensated stage of hepatitis B cirrhosis, which requires early clinical intervention, so the early diagnosis of hepatorenal syndrome is crucial. This study establishes a new predictive model based on serum biomarkers for the early diagnosis of hepatorenal syndrome.
87. The effect of Benson relaxation technique on the severity of symptoms and quality of life in children with irritable bowel syndrome (IBS): a quasi-experimental study.
作者: Saba Ebrahimloee.;Anahita Masoumpoor.;Malihe Nasiri.;Mohadese Babaie.;Amirparsa Vanaki Farahani.;Sepideh Yousefiasl.;Azam Shirinabadi Farahani.
来源: BMC Gastroenterol. 2022年22卷1期547页
This study aimed to determine the effect of the Benson relaxation technique on the severity of symptoms and quality of life in children with irritable bowel syndrome (IBS).
89. Computer-aided Detection of Polyps Does Not Improve Colonoscopist Performance in a Pragmatic Implementation Trial.
作者: Uri Ladabaum.;John Shepard.;Yingjie Weng.;Manisha Desai.;Sara J Singer.;Ajitha Mannalithara.
来源: Gastroenterology. 2023年164卷3期481-483.e6页 90. Application of a WeChat-based mini-app as a patient reminder in Helicobacter pylori eradication: a prospective multi-center randomized controlled study.
作者: Kefang Sun.;Yishu Chen.;Zhenzhen Wang.;Yi Liu.;Yue Pan.;Xinli Mao.;Lei Xu.;Chaohui Jin.;Ming Chen.;Chaohui Yu.;Lan Li.
来源: BMC Gastroenterol. 2022年22卷1期520页
To improve the eradication rate of H. pylori, researchers have investigated the role of WeChat-based mini-app as an electronic reminding system in H. pylori treatment.
91. Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy.
作者: Jian-Xu Li.;Mei-Ling He.;Mo-Qin Qiu.;Liu-Ying Yan.;Mei-Ying Long.;Jian-Hong Zhong.;Rui-Jun Zhang.;Chun-Feng Liang.;Ya-Dan Pang.;Jun-Kun He.;Qian-Qian Chen.;Jin-Xia Weng.;Shi-Xiong Liang.;Bang-De Xiang.
来源: BMC Gastroenterol. 2022年22卷1期510页
For patients with unresectable hepatocellular carcinoma (uHCC), intensity-modulated radiotherapy (IMRT) has become one of the options for clinical local treatment. Immune parameters, including platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR) and systemic immune inflammatory (SII), predict survival in various cancers. This study aimed to determine whether peripheral immune parameters can predict survival in patients with uHCC undergoing IMRT and establish a clinically useful prognostic nomogram for survival prediction.
92. Change lifestyle modification plan/transtheoretical model in non-alcoholic simple fatty liver disease: a pilot randomized study.
Non-alcoholic simple fatty liver disease patients have very low compliance with almost all types of physical activities. A transtheoretical model-oriented lifestyle modification plan awakens the patient's consciousness in the pre-intention stage. Aim to evaluate whether a management by stages of change plan based on the Transtheoretical Model and Stages of Change promoted behavior change for patients with non-alcoholic simple fatty liver disease.
93. An extended 36-week oral esomeprazole improved long-term recurrent peptic ulcer bleeding in patients at high risk of rebleeding.
作者: Hsueh-Chien Chiang.;Er-Hsiang Yang.;Huang-Ming Hu.;Wei-Ying Chen.;Wei-Lun Chang.;Chung-Tai Wu.;Deng-Chyang Wu.;Bor-Shyang Sheu.;Hsiu-Chi Cheng.
来源: BMC Gastroenterol. 2022年22卷1期439页
Patients with Rockall scores ≥6 have an increased risk of long-term peptic ulcer rebleeding. This study was aimed toward investigating whether an extended course of oral esomeprazole up to 1 year decreased ulcer rebleeding in such patients.
94. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
作者: Loren Laine.;Kenneth DeVault.;Philip Katz.;Stefan Mitev.;John Lowe.;Barbara Hunt.;Stuart Spechler.
来源: Gastroenterology. 2023年164卷1期61-71页
For decades, proton pump inhibitors (PPIs) have been the mainstay of treatment for erosive esophagitis. The potassium-competitive acid blocker vonoprazan provides more potent acid inhibition than PPIs, but data on its efficacy for erosive esophagitis are limited.
95. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.
作者: C Fiorella Murillo Perez.;Holly Fisher.;Shaun Hiu.;Dorcas Kareithi.;Femi Adekunle.;Tracy Mayne.;Elizabeth Malecha.;Erik Ness.;Adriaan J van der Meer.;Willem J Lammers.;Palak J Trivedi.;Pier Maria Battezzati.;Frederik Nevens.;Kris V Kowdley.;Tony Bruns.;Nora Cazzagon.;Annarosa Floreani.;Andrew L Mason.;Albert Parés.;Maria-Carlota Londoño.;Pietro Invernizzi.;Marco Carbone.;Ana Lleo.;Marlyn J Mayo.;George N Dalekos.;Nikolaos K Gatselis.;Douglas Thorburn.;Xavier Verhelst.;Aliya Gulamhusein.;Harry L A Janssen.;Rachel Smith.;Steve Flack.;Victoria Mulcahy.;Michael Trauner.;Christopher L Bowlus.;Keith D Lindor.;Christophe Corpechot.;David Jones.;George Mells.;Gideon M Hirschfield.;James Wason.;Bettina E Hansen.; .
来源: Gastroenterology. 2022年163卷6期1630-1642.e3页
The Primary Biliary Cholangitis (PBC) Obeticholic Acid (OCA) International Study of Efficacy (POISE) randomized, double-blind, placebo-controlled trial demonstrated that OCA reduced biomarkers associated with adverse clinical outcomes (ie, alkaline phosphatase, bilirubin, aspartate aminotransferase, and alanine aminotransferase) in patients with PBC. The objective of this study was to evaluate time to first occurrence of liver transplantation or death in patients with OCA in the POISE trial and open-label extension vs comparable non-OCA-treated external controls.
96. Bowel preparation using 2-L split-dose polyethylene glycol regimen plus lubiprostone versus 4-L split-dose polyethylene glycol regimen: a randomized controlled trial.
作者: Apichet Sirinawasatien.;Pallop Sakulthongthawin.;Kanokpoj Chanpiwat.;Tanyaporn Chantarojanasiri.
来源: BMC Gastroenterol. 2022年22卷1期424页
Colonoscopy is a standard procedure for evaluating colon diseases and screening for colorectal cancer, and bowel cleanliness prior to colonoscopy is key. The aim of this study was to compare the bowel cleansing efficacy of low-volume (2 L) split-dose polyethylene glycol (PEG) plus single-dose (24 µg) lubiprostone (LB) and high-volume (4 L) split-dose PEG.
97. Transient alterations in plasma sodium concentrations with NER1006 bowel preparation: an analysis of three phase III, randomized clinical trials.
This analysis characterized changes in sodium levels in patients receiving the 1 L polyethylene glycol-based preparation NER1006.
98. Efficacy and safety of subanesthetic doses of esketamine combined with propofol in painless gastrointestinal endoscopy: a prospective, double-blind, randomized controlled trial.
作者: Yongtong Zhan.;Shuqing Liang.;Zecheng Yang.;Qichen Luo.;Shuai Li.;Jiamin Li.;Zhaojia Liang.;Yalan Li.
来源: BMC Gastroenterol. 2022年22卷1期391页
Painless gastrointestinal endoscopy is widely used for the diagnosis and treatment of digestive diseases. At present, propofol is commonly used to perform painless gastrointestinal endoscopy, but the high dose of propofol often leads to a higher incidence of cardiovascular and respiratory complications. Studies have shown that the application of propofol combined with ketamine in painless gastrointestinal endoscopy is beneficial to reduce the dosage of propofol and the incidence of related complications. Esketamine is dextrorotatory structure of ketamine with a twice as great anesthetic effect as normal ketamine but fewer side effects. We hypothesized that esketamine may reduce the consumption of propofol and to investigate the safety of coadministration during gastrointestinal endoscopy.
99. Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study.
作者: Baili Chen.;Jie Zhong.;Xiuling Li.;Feng Pan.;Yijuan Ding.;Yan Zhang.;Hong Chen.;Fei Liu.;Zhenyu Zhang.;Ling Zhang.;Rafal Drozda.;Oleksandr Oliinyk.;Aik Han Goh.;Xiang Chen.;Xiang Sun.;David T Rubin.;William J Sandborn.;Minhu Chen.
来源: Gastroenterology. 2022年163卷6期1555-1568页
Current therapies for ulcerative colitis (UC) fail to achieve satisfactory disease control. Selective inhibition of Janus kinase (JAK) type 1 may improve clinical outcomes in patients with UC while avoiding the side effects associated with pan-JAK inhibition. The safety and efficacy of the selective JAK1 inhibitor ivarmacitinib (formerly SHR0302) were evaluated in patients with moderate-to-severe, active UC.
100. Comparison of anal dilatation versus no dilatation with a standardized dilator in reducing pain after hemorrhoidectomy: a randomized control trial.
作者: Imam Sofii.;Handy Darmawan.;Amelia Sophia Ramadhini.;Fauzan Kurniawan.;Ahmad Shafa Hanif.
来源: BMC Gastroenterol. 2022年22卷1期379页
Post-operative pain is the main problem of hemorrhoidectomy. An adequate pain management can promote early mobilization, fast recovery, and reduce hospitalization costs. This study aimed to investigate the role of preoperative anal dilatation using a standardized anal dilator in reducing post-operative pain.
|